Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Scrip

APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong

By Ian Haydock 01 Dec 2021

Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.

Pharma Intelligence Apps

Not all news services are created equal

30 Nov 2021

Pharma Insights team of trusted journalists bring you the most critical news and analysis round the clock. Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments. Register for your free trial today to find out what our editors and journalists are reporting on now.

Scrip

COVID-19 Vaccine Makers Pledge Rapid Response To Omicron Threat

By Andrew McConaghie 29 Nov 2021

While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 28 Nov 2021

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.

Scrip

Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies

By Mandy Jackson 25 Nov 2021

Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.

Scrip

Moderna Co-Founder Robert Langer’s Tips For Innovation

By Vibha Ravi 22 Nov 2021

Moderna co-founder Robert Langer shared tips to drive innovation at a recent summit, while narrating a fascinating tale of tenacity during the development of angiogenesis inhibitors with Judah Folkman. If an idea is important, it’s sure to be criticized, said the man who has over 1,000 patents issued or pending worldwide.

Pharma Competitive Intelligence

Not all biopharma IPOs are created equal.

18 Nov 2021

Scrip's team of trusted industry experts bring you the mos critical news and analysis on key commercial topics, from licensing to clinical trials, and competitor activity, around the clock. Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments. Register for your free trial today to find out what our editors and journalists are reporting on now.

Pharma Intelligence Apps

Not all generics firms are created equal

18 Nov 2021

Get unrivalled coverage, news, and analysis of the global generics, biosimilars, and value-added medicines industries from the industry experts at Generics Bulletin. Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments. Register for your free trial today to find out what our editors and journalists are reporting on now.

Scrip

Pfizer’s Bourla On Paxlovid Patent Deal And Why A Similar Approach Won't Work For Comirnaty

By Alaric DeArment 17 Nov 2021

Pfizer CEO Albert Bourla discussed the emergency use authorization filing for Paxlovid, expanding access to the COVID-19 pill in lower income countries and booster shots, at the STAT Summit.

Scrip

BI And Lilly Eye Acute Heart Failure Opportunity For Jardiance

By Kevin Grogan 16 Nov 2021

Having strongly made the case for Jardiance as a treatment for chronic heart failure, Boehringer Ingelheim and Eli Lilly believe the SGLT2 inhibitor could have a lot of potential in acute heart failure as well after promising data from the EMPULSE study.

Scrip

Quick Listen: Scrip’s Five Must-Know Things

By Ian Haydock 15 Nov 2021

In this week's podcast edition of Five Must-Know Things: Pfizer’s "game-changing" COVID-19 oral antiviral results; Novartis sells Roche stake; Novartis trumps productive pipeline; Bayer sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.

Scrip

AstraZeneca Signs First COVID-19 Vaccine For-Profit Deals

By Andrew McConaghie 12 Nov 2021

AstraZeneca is one of the sector’s top growth stories in 2021, but controversies around its COVID-19 vaccine continue to grab headlines, and Chinese price cuts bite.

Citeline, Trialtrove: gold standard clinical trials intellig...

2020 Clinical Trials Roundup: Disruptions to the Trial Landscape

03 Nov 2021

Our annual analysis dissects the data of all Phase I–III clinical trials that started in a year dominated by COVID-19.

Scrip

Comirnaty Gives Booster Shot To Pfizer Q3 Sales

By Alaric DeArment 02 Nov 2021

Pfizer-BioNTechvaccineinglovedhand-1230011145

The company increased its guidance for sales of the COVID-19 vaccine again, to $36bn, though many other products’ sales were close to or below analyst expectations.

Scrip

Approval Delayed, But Janssen/Legend’s Cilta-Cel May Hit Market Just In Time

By Mandy Jackson 02 Nov 2021

The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.